進行性固形腫瘍を有する成人参加者におけるIDE574療法の安全性、薬物動態、および予備的効果を調査する研究
An Open Label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of IDE574 as Monotherapy in Locally Advanced or Metastatic Solid Tumors and as Combination Therapy With Fulvestrant in Locally Advanced or Metastatic Cancer
IDE574 is a synthetically manufactured small molecule inhibitor that co-targets the lysine acetyltransferase enzymes KAT6 and KAT7.
The purpose of this study is to evaluate the safety, preliminary efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of IDE574 as monotherapy in participants with locally advanced or metastatic solid tumors and as combination therapy with fulvestrant in participants with advanced or metastatic cancer.
調査の概要
詳細な説明
Part 1 - Monotherapy Dose Escalation and Expansion:
Part 1A - Monotherapy Dose Escalation Part 1A will evaluate increasing doses of IDE574 to assess safety, tolerability and to determine dose-limiting toxicities (DLTs), the maximum tolerated dose (MTD) or the recommended dose for expansion (RDE) in subjects with advanced or metastatic cancer.
Part 1B - Monotherapy Dose Expansion Part 1B will evaluate in ER+ HER2- advanced or metastatic cancer at one RDE determined from Part 1A or the MTD.
Part 1C - Exploratory Food Effect Sub-study
Part 2 - Combination Dose Escalation and Expansion
Part 2A - IDE574 Combination Therapy with Fulvestrant Dose Escalation Part 2A will evaluate participants with advanced or metastatic cancer with escalating doses of IDE574 in combination with fulvestrant to assess safety, tolerability and to determine DLTs, MTD or RDE.
Part 2B - IDE574 Combination Therapy with Fulvestrant Dose Expansion Part 2B will randomly assign participants with advanced or metastatic cancer to dose levels selected from Part 2A
研究の種類
入学 (推定)
段階
- フェーズ 1
連絡先と場所
研究連絡先
- 名前:IDEAYA Clinical Trials
- 電話番号:+1-855-433-224
- メール:IDEAYAClinicalTrials@ideayabio.com
研究場所
-
-
California
-
Santa Monica、California、アメリカ、90404-2095
- 積極的、募集していない
- UCLA - Parkside Cancer Center
-
-
Connecticut
-
New Haven、Connecticut、アメリカ、06510-3206
- 募集
- Yale School of Medicine - Cedar Street
-
主任研究者:
- Patricia LoRusso, MD
-
コンタクト:
- Karen Seely
- 電話番号:203-314-3303
- メール:karen.rodriguezvasquez@yale.edu
-
-
Florida
-
Plantation、Florida、アメリカ、33322
- 募集
- Florida Clinical Trials Group
-
主任研究者:
- Harshad Amin, MD
-
コンタクト:
- Sandra Perez
- 電話番号:772-297-3057
- メール:perezs@floridactg.com
-
-
Georgia
-
Atlanta、Georgia、アメリカ、30322-1013
- 募集
- Winship Cancer Institute, Emory University
-
主任研究者:
- Shipra Gandhi, MD
-
コンタクト:
- Alejandra Bono
- 電話番号:404-778-0954
- メール:alejandra.maria.bono@emory.edu
-
-
Missouri
-
St Louis、Missouri、アメリカ、63110-1010
- 募集
- Washington University - Siteman Cancer Center
-
主任研究者:
- Faisal Fa'ak, MD
-
コンタクト:
- Pamela Coe
- 電話番号:314-747-7569
- メール:mpamela@wustl.edu
-
-
New Jersey
-
East Brunswick、New Jersey、アメリカ、08816
- 募集
- START Astera, LLC
-
主任研究者:
- Bruno Fang, MD
-
コンタクト:
- Bruno S Fang
- 電話番号:732-426-4750
- メール:info@startresearch.com
-
-
New York
-
Lake Success、New York、アメリカ、11042
- 募集
- START New York Long Island, LLC
-
主任研究者:
- Geraldine O'Sullivan Coyne, MD
-
コンタクト:
- Geraldine O'Sullivan Coyne
- 電話番号:363-207-5160
- メール:g.osullivancoyne@startresearch.com
-
New York、New York、アメリカ、10032-3729
- 積極的、募集していない
- Columbia University Medical Center -161 Fort Washington
-
-
Tennessee
-
Nashville、Tennessee、アメリカ、37203
- 募集
- SCRI Oncology Partners - PPDS
-
主任研究者:
- Sarah Premji, MD
-
コンタクト:
- Connor Frost
- 電話番号:615-478-3475
- メール:connor.frost@scri.com
-
-
Texas
-
Austin、Texas、アメリカ、78758
- 募集
- NEXT Texas LLC - Austin
-
主任研究者:
- Sheena Sahota, MD
-
コンタクト:
- Heather Watson
- 電話番号:737-610-5202
- メール:nxtaus_coordinators@nextoncology.com
-
Dallas、Texas、アメリカ、75039
- 募集
- NEXT Texas LLC - Dallas
-
主任研究者:
- Faran Polani, MD
-
コンタクト:
- Carmen Gonzalez
- 電話番号:210-580-9479
- メール:NXTDFW_Coordinators@nextoncology.com
-
Fort Worth、Texas、アメリカ、76104
- 募集
- START Dallas Fort Worth, LLC
-
主任研究者:
- Henry Xiong, MD
-
コンタクト:
- Henry Xiong
- 電話番号:682-350-3010
- メール:info@startresearch.com
-
Houston、Texas、アメリカ、77030-4009
- 募集
- MD Anderson Cancer Center
-
主任研究者:
- Timothy Yap, MD
-
コンタクト:
- Desirae Dufner
- 電話番号:713-524-3434
- メール:DDufner@mdanderson.org
-
Houston、Texas、アメリカ、77054
- 募集
- NEXT Texas LLC - Houston
-
主任研究者:
- Jennifer Segar, MD
-
コンタクト:
- Carmen Gonzalez
- 電話番号:210-580-9479
- メール:nxthou_coordinators@nextoncology.com
-
San Antonio、Texas、アメリカ、78229
- 募集
- NEXT Texas LLC - San Antonio
-
主任研究者:
- David Sommerhalder, MD
-
コンタクト:
- April Guerra
- 電話番号:210-580-9500
- メール:NXTSA_Coordinators@nextoncology.com
-
San Antonio、Texas、アメリカ、78229
- 募集
- Start San Antonio, LLC
-
主任研究者:
- Amita Patnaik, MD
-
コンタクト:
- Hector Navarro
- 電話番号:210-593-5700
- メール:Hector.Navarro@startresearch.com
-
-
Utah
-
West Valley City、Utah、アメリカ、84119
- 募集
- START Mountain Region, LLC
-
主任研究者:
- William McKean, MD
-
コンタクト:
- William B McKean
- 電話番号:1 (801) 907-4750
- メール:info@startresearch.com
-
-
Virginia
-
Fairfax、Virginia、アメリカ、22031
- 募集
- NEXT Virginia
-
主任研究者:
- Mohamad Salkeni, MD
-
コンタクト:
- Maybelle De La Rosa
- 電話番号:703-783-4518
- メール:nxtvir_coordinators@nextoncology.com
-
-
-
-
K'alak'i T'bilisi
-
Batumi、K'alak'i T'bilisi、グルジア、6000
- 募集
- High Technology Hospital MedCenter Ltd
-
主任研究者:
- Tamta Makharadze, MD
-
コンタクト:
- Mamuka Sikharulidze
- 電話番号:+995 568 999 559
- メール:sikharulidzemamuka3@gmail.com
-
Tbilisi、K'alak'i T'bilisi、グルジア、114
- 募集
- Pineo Medical Ecosystem
-
コンタクト:
- Nino Kekenadze
- 電話番号:+995 593 660 940
- メール:Nkekenadze@pineo.ge
-
主任研究者:
- Mziuri Zakaraia, MD
-
Tbilisi、K'alak'i T'bilisi、グルジア、112
- 積極的、募集していない
- LLC ARENSIA Exploratory Medicine
-
Tbilisi、K'alak'i T'bilisi、グルジア、144
- 積極的、募集していない
- Geo Hospitals Multiprofile Medical Center Tbilisi
-
Tbilisi、K'alak'i T'bilisi、グルジア、186
- 積極的、募集していない
- LLC Caucasus Medical Centre
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
Archival Tissue sample for testing
- Part 1A - Participants with advanced or metastatic cancer who have progressed on/after standard of care therapy or are intolerant to additional effective therapies.
- Female participants with cancer considered to be of childbearing potential (or have tubal ligations only) must be willing to undergo medically induced menopause (Parts 2A and B only)
- Female participants of nonchildbearing potential with cancer must meet at least 1 of the following criteria: Age ≥ 60 years or age <60 years with absence of menstruation for at least 12 months, or had prior removal of both ovaries
- Have Eastern Cooperative Oncology Group performance status (ECOG PS) of ≤1.
- Have adequate bone marrow, renal and liver function.
- Life expectancy of >3 months
- Able to safely administer and retain orally administered study treatment
- Able to comply with contraceptive/barrier requirements
Key Exclusion Criteria:
- Known symptomatic brain metastases or leptomeningeal metastasis
- Known primary CNS malignancy and any other malignancies within 2 years prior to the first dose with the exception of adequately treated localized tumor.
- Have impairment of GI function or GI disease that may significantly alter the absorption of IDE574.
- Have active liver or biliary disease.
- Have active, uncontrolled bacterial, fungal, or viral infection
- Have clinically significant cardiac abnormalities and/or blood clotting events within 6 months before the first dose
- If participants had adverse reactions to previous experimental antitumor treatment that have not recovered to Grade ≤ 1
- Prior irradiation to >25% of the bone marrow.
- Known or suspected hypersensitivity to IDE574/excipients or components (Parts 1 & 2) or fulvestrant/excipients or components (Part 2 only)
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Monotherapy Dose Escalation (Part 1A)
Participants with the appropriate tumor types will be treated with escalating doses of IDE574 |
IDE574 |
|
実験的:Monotherapy Dose Expansion (Part 1B)
Participants with advanced or metastatic cancer will be treated using the RDE or MTD of IDE574 |
IDE574 |
|
実験的:Combination Dose Escalation (Part 2A) IDE574 + Fulvestrant
Participants with advanced or metastatic cancer will be treated with escalating doses of IDE574 in combination with fulvestrant |
IDE574 Fulvestrant Injection |
|
実験的:Combination Dose Expansion (Part 2B)
Participants with advanced or metastatic cancer will be randomly assigned to doses of IDE574 + Fulvestrant |
IDE574 Fulvestrant Injection |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Safety and Tolerability of IDE574 in Part 1 A Monotherapy Dose escalation
時間枠:Following the first dose of IDE574
|
incidence of DLT; incidence and severity of AEs/serious adverse events (SAEs) graded based on CTCAE V6.0 |
Following the first dose of IDE574
|
|
Safety and Tolerability of IDE574 in Part 1B Monotherapy Dose expansion based on incidence and severity of AEs/SAEs
時間枠:total study duration
|
Incidence and severity of AEs/SAEs graded based on CTCAE V6.0 |
total study duration
|
|
To evaluate anti-tumor activity of IDE574 in Part 1B Monotherapy Dose expansion based on the ORR per RECIST version 1.1
時間枠:total study duration
|
Objective Response Rate (ORR) per RECIST version 1.1 will be calculated based on the proportion of participants with confirmed Complete Response or Partial Response |
total study duration
|
|
To evaluate anti-tumor activity of IDE574 in Part 1B Monotherapy Dose expansion based on DOR per RECIST version 1.1.
時間枠:total study duration
|
Duration of response (DOR) per RECIST version 1.1 will be calculated based on the proportion of participants with confirmed Complete Response or Partial Response |
total study duration
|
|
Safety and tolerability of IDE574 in combination with Fulvestrant in Part 2A Combination Dose Escalation based on incidence of DLT
時間枠:total study duration
|
Incidence of DLT; incidence and severity of AEs/SAEs graded based on CTCAE V6.0 |
total study duration
|
|
Safety and tolerability of IDE574 in combination with Fulvestrant in Part 2B Combination Dose Expansion based on the incidence and severity of AEs/SAEs
時間枠:total study duration
|
Incidence and severity of AEs/SAEs graded based on CTCAE V6.0 |
total study duration
|
|
Anti-tumor activity of IDE574 in combination with Fulvestrant in Part 2B Combination Dose Expansion based on the ORR per RECIST version 1.1
時間枠:total study duration
|
Objective Response Rate (ORR) per RECIST version 1.1 will be calculated based on the proportion of participants with confirmed Complete Response or Partial Response |
total study duration
|
|
Anti-tumor activity of IDE574 in combination with Fulvestrant in Part 2B Combination Dose Expansion based on DOR per RECIST version 1.1.
時間枠:total study duration
|
Duration of response (DOR) per RECIST version 1.1 will be calculated based on the proportion of participants with confirmed Complete Response or Partial Response |
total study duration
|
二次結果の測定
結果測定 |
時間枠 |
|---|---|
|
Evaluate the preliminary antitumor activity of IDE574 in Part 1A Monotherapy Dose Escalation based on the ORR per RECIST version 1.1
時間枠:total study duration
|
total study duration
|
|
Evaluate the preliminary antitumor activity of IDE574 in Part 1A Monotherapy Dose Escalation based on DOR per RECIST version 1.1.
時間枠:total study duration
|
total study duration
|
|
Evaluate the preliminary antitumor activity of IDE574 in Part 1A Monotherapy Dose Escalation based on Clinical Benefit Rate (CBR)
時間枠:total study duration
|
total study duration
|
|
Evaluate the preliminary antitumor activity of IDE574 in Part 1A Monotherapy Dose Escalation based on Disease control rate
時間枠:total study duration
|
total study duration
|
|
Evaluate the pharmacokinetics (PK) of IDE574 in Part 1A Monotherapy Dose Escalation
時間枠:total study duration
|
total study duration
|
|
Evaluate the PK of IDE574 in Part 1B Monotherapy Dose Expansion
時間枠:total study duration
|
total study duration
|
|
Evaluate antitumor activity of IDE574 in Part 1B Monotherapy Dose Expansion
時間枠:total study duration
|
total study duration
|
|
Evaluate antitumor activity of IDE574 in Part 1B Monotherapy Dose Expansion based on DCR for other solid tumor types
時間枠:total study duration
|
total study duration
|
|
Evaluate the preliminary antitumor activity of IDE574 in combination with Fulvestrant Part 2A Combination Dose Escalation based on ORR per RECIST version 1.1
時間枠:total study duration
|
total study duration
|
|
Evaluate the preliminary antitumor activity of IDE574 in combination with Fulvestrant Part 2A Combination Dose Escalation based on DOR per RECIST version 1.1
時間枠:total study duration
|
total study duration
|
|
Evaluate the preliminary antitumor activity of IDE574 in combination with Fulvestrant Part 2A Combination Dose Escalation based on CBR per RECIST version 1.1
時間枠:total study duration
|
total study duration
|
|
Evaluate the PK of IDE574 in Part 2A Combination Dose Escalation
時間枠:total study duration
|
total study duration
|
|
Evaluate antitumor activity of IDE574 in combination with Fulvestrant in Part 2B Combination Dose Expansion based on CBR per RECIST version 1.1
時間枠:total study duration
|
total study duration
|
|
Evaluate the PK of IDE574 in Part 2B Combination Dose Expansion
時間枠:total study duration
|
total study duration
|
協力者と研究者
スポンサー
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- IDE574-001
- 178299 (その他の識別子:Regulatory Agency Identifier Number (s))
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。